Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyra Therapeutics, Inc. (Nasdaq: LYRA) SEC filings page on Stock Titan provides access to the company’s public reports and current reports filed with the U.S. Securities and Exchange Commission. Lyra identifies itself in these filings as a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis (CRS), with its common stock listed on The Nasdaq Capital Market under the symbol LYRA.
Through Lyra’s Forms 10-K and 10-Q, readers can review detailed financial statements, including collaboration revenue, research and development expenses related to the ENLIGHTEN Phase 3 clinical program for LYR-210, general and administrative costs, restructuring charges, and cash and cash equivalents balances. These periodic reports also describe the company’s status as a clinical-stage entity with no approved products and discuss risks such as ongoing losses, funding needs, and dependence on clinical trial outcomes.
Current reports on Form 8-K document material events that are important for understanding LYRA’s situation. Examples include notices from The Nasdaq Stock Market regarding compliance with listing requirements, such as minimum bid price and stockholders’ equity thresholds; details of a registered direct offering and concurrent private placement of warrants; and changes in board and executive roles. Other 8-K filings reference the posting of corporate presentations that discuss LYR-210 and the ENLIGHTEN clinical program.
For those interested in clinical and strategic developments, Lyra’s filings and attached exhibits often cross-reference press releases that summarize ENLIGHTEN 2 Phase 3 results, pooled analyses in patients with nasal polyps, and regulatory interactions with the U.S. Food and Drug Administration. More recent corporate updates, including the decision by Lyra’s Board of Directors to suspend further development of LYR-210 and cease product development operations, are reflected in company disclosures and provide important context for interpreting financial and risk disclosures.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered tools can help readers quickly identify key sections in lengthy reports, such as risk factors, management’s discussion and analysis, restructuring notes, and disclosures related to Nasdaq listing status, financing agreements, and strategic alternatives under consideration.
Lyra Therapeutics filed a Form 25 notifying removal of its Common Stock from The Nasdaq Capital Market. The company submitted the notification on April 20, 2026. The filing covers Common Stock, par value $0.001 per share, and is submitted under Section 12(b) of the Exchange Act.
Lyra Therapeutics, Inc. has terminated its sublease for approximately 23,704 rentable square feet at 880 Winter Street in Waltham, Massachusetts. The sublease, originally dated December 21, 2023, terminated effective March 31, 2026, with the premises to be surrendered no later than May 31, 2026.
As part of the termination, Lyra agreed to pay a termination payment of $2,100,000.00. After Lyra completes its surrender obligations and this payment is made, RVAC Medicines (US), Inc. will release and return Lyra’s $600,501.32 letter of credit security deposit. The company’s rent obligations under the sublease ended on January 31, 2026.
Lyra Therapeutics is exiting two Massachusetts office leases earlier than planned in exchange for cash payments and forfeited deposits. The company agreed with ARE-480 Arsenal Street, LLC to end its 480 Arsenal Way lease for approximately 22,343 rentable square feet no later than May 31, 2026, instead of April 30, 2027. Lyra will forfeit a $302,514.84 letter of credit security deposit, pay a $1,000,000.00 lease modification amount, and potentially pay up to $1,500,000.00 more if a defined sale transaction closes. Rent obligations for this site ended as of January 31, 2026.
For its 880 Winter Street, Waltham lease covering approximately 28,858 rentable square feet, Lyra entered a termination agreement with BXP Waltham Woods LLC to end the lease on May 31, 2026 instead of June 30, 2033. The company will forfeit a $1,089,389.00 letter of credit security deposit and pay a $1,500,000.00 termination fee as liquidated damages, with rent obligations ending March 31, 2026. The agreement includes mutual releases effective at termination.
Lyra Therapeutics director and Principal Executive Officer Maria Palasis reported returning 2,000 shares of Common Stock to the company in a disposition to the issuer at $0.00 per share. After this transaction, she directly owns 1,094,733 shares, indicating only a small portion of her holdings was affected.
Lyra Therapeutics Principal Financial Officer Jason Cavalier returned 667 shares of Common Stock to the company. The disposition to the issuer carried a reported price of $0.00 per share. After this transaction, he directly owns 517,880 shares, indicating this was a small, routine adjustment to his holdings.
Lyra Therapeutics reports in its annual filing that it has suspended further development of LYR-210, its lead chronic rhinosinusitis treatment, and implemented deep cost reductions, including layoffs affecting substantially all remaining employees. The company is pursuing strategic alternatives such as a merger, sale, or asset transactions but notes there is no assurance any deal will occur or be attractive.
Lyra highlights serious financial strain, with operating losses of approximately $31.0 million in 2025 and $96.3 million in 2024 and acknowledges substantial doubt about its ability to continue as a going concern. It is attempting to sublease or assign costly leases, while facing delisting from the Nasdaq Capital Market and potential classification as a public shell company, which could severely limit liquidity, capital-raising options, and use of Rule 144 and Form S‑3. The company has positive Phase 3 ENLIGHTEN 2 data for LYR-210 and an extensive patent estate potentially extending to 2042, but any renewed development would require significant new funding or a strategic transaction.